EFFECTS OF SGLT2 INHIBITORS ON CARDIOVASCULAR OUTCOMES WITH AND WITHOUT BASELINE USE OF GLP-1 RECEPTOR AGONISTS: A SMART-C COLLABORATIVE META-ANALYSIS
Brendon L. Neuen(The George Institute for Global Health), Hiddo J.L. Heerspink(University Medical Center Groningen), Robert A. Fletcher(UNSW Sydney), Ellen M. Apperloo(Dialyse Centrum Groningen)
Cited by 1
Related Papers
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k
Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis
|The Lancet|2012|1.4k
Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
|New England Journal of Medicine|2013|990